Adipose derived stem cell therapy market is witnessing massive growth as Tissue Genesis announces positive treatment results for a group of a patient treated with Icellator X Technology

Adipose stem cells are cells taken from the patient's own fat and then injected into the patient to treat certain diseases and afflictions. Adipose-derived stem cells are unique in that they can be used in many different areas and the procedure is referred to as adipose stem cell therapy. In some countries, these cells are taken from the abdomen and used in liposuction, whereas other countries limit the use of such cells. Adipose-derived stem cells are gaining significant traction and appeal as new cell sources in regenerative medicine therapies. Regenerative medicines offer accelerated healing, reduced inflammation, and pain, and improves tissues and bones. The continuous research and development activities in the field of regenerative medicines can stimulate the demand for adipose-derived stem cells. Recently, in January 2020, Takara Bio Inc. inaugurated a new facility, ‘Center for Gene and Cell Processing II’ for research and manufacturing of regenerative medicine products in Kusatsu, Japan. Thus, such activities can augment growth of the adipose derived stem cell therapy market. 

Adipose Derived Stem Cell Therapy

 

There are several different ways in which the cells can be used. One of these methods is known as intrauterine insemination, which is the process of injecting the cells into the fallopian tubes. After they travel down the fallopian tubes they are then placed into the uterus. When it comes to geographical footprint, North America remains one of the leading adopters of adipose-derived stem cell therapy. This is typically due to the fact that increase in product offerings, presence of key major market players, and increase in research and development activity. Similarly, Asia Pacific is also exhibiting promising signs in adipose derived stem cell therapy market. Increase in demand for adipose-derived stem cell products for the treatment of musculoskeletal diseases can enhance the regional market growth.

Recently, in August 2019, Tissue Genesis, a developer of cell therapy processing systems, announced the results for its Icellator X Technology, mentioning that the initial group of patients was successfully treated. New technology produces higher yields of stem cells to enhance patient treatments.

That being said, the stem cell process is significantly expensive and time-consuming, which makes it challenging to push for its wider adoption. Besides, there numerous technical limitations related to preservation and ethical issues regarding the use of allogeneic stem cell lines. Thus, such adversities could potentially inhibit the growth of the adipose derived stem cell therapy market in the near future.

The demand for adipose derived stem therapy is also driven by an increase in public as well as private funding to support stem cell-based researches. Besides, in the recent past, there has been an increase in regulatory approvals for adipose-derived stem cells targeted clinical trials across the globe. Such positive factors can stimulate growth of the adipose derived stem cell therapy in the near future.

Comments

Popular posts from this blog

Increasing Initiatives to Digitalize the Healthcare Sector Is Expected To Boost Demand for Electronic Medical Records

Potential of Indian Tourism

Nanocoatings are viable and give security from different ecological components